Androgens and epithelial ovarian cancer: What's the connection?

Cancer Biology and Therapy

Volumn 7, Issue 11, 2008, Pages 1712-1716

  Li, Andrew J ^a,b   Karlan, Beth Y ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Androgen receptor; Androgens; Epidermal growth factor; Epithelial ovarian cancer; Risk; Survival; Tumor growth factor beta

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; ANDROSTANOLONE; ANDROSTENEDIONE; ANTIANDROGEN; BICALUTAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUTAMIDE; GOSERELIN; MITOGEN ACTIVATED PROTEIN KINASE; PRASTERONE; TESTOSTERONE; TRANSFORMING GROWTH FACTOR BETA;

ANDROGEN BLOOD LEVEL; ANDROSTENEDIONE BLOOD LEVEL; CANCER REGRESSION; CANCER RISK; CARCINOGENESIS; CLINICAL EVALUATION; CLINICAL TRIAL; EPITHELIAL OVARIAN CANCER; EPITHELIUM TUMOR; GENE EXPRESSION; HUMAN; KIDNEY CELL CULTURE; OUTCOME ASSESSMENT; OVARY CANCER; PATHOPHYSIOLOGY; REVIEW; BIOLOGICAL MODEL; CLINICAL TRIAL (TOPIC); FEMALE; GENE EXPRESSION REGULATION; METABOLISM; ONCOLOGY; OVARY TUMOR; PROCEDURES; SIGNAL TRANSDUCTION;

ANDROGENS; CLINICAL TRIALS AS TOPIC; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MEDICAL ONCOLOGY; MODELS, BIOLOGICAL; OVARIAN NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 56449097463     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.7.11.7054     Document Type: Review

References (59)

1. Spurdle AB, Webb PM, Chen X, Martin NG, Giles GG, Hopper JL, Chenevix-Trench G. Androgen receptor exon 1 CAG repeat length and risk of ovarian cancer. Int J Cancer 2000; 87:637-43.
2. Tut TG, Ghadessy FJ, Trifiro MA, Pinsky L, Yong EL. Long polyglutamine tracts in the androgen receptor are associated with reduced trans-activation, impaired sperm production and male infertility. J Clin Endocrinol Metabol 1997; 82:3777-82.
3. Chamberlain NL, Driver ED, Miesfeld RL. The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function. Nucleic Acids Res 1994; 22:3181-6.
4. Buchanan G, Yang M, Cheong A, Harris JM, Irvine RA, Lambert PF, Moore NL, Raynor M, Neufing PJ, Coetzee GA, Tilley WD. Structural and functional consequences of glutamine tract variation in the androgen receptor. Hum Mol Genet 13:1677-92.
5. Li AJ, Scoles DR, Armstrong KU, Karlan BY. Androgen receptor cytosine-adenine-guanine repeat polymorphisms modulate EGFR signaling in epithelial ovarian carcinomas. Gynecol Oncol 2008; 109:220-5.
6. Edmondson RJ, Monaghan JM, Davies BR. The human ovarian surface epithelium is an androgen responsive tissue. Br J Cancer 2002; 86:879-85.
7. Karlan BY, Karlan BY, Jones J, Greenwald M, Lagasse LD. Steroid hormone effects on the proliferation of human ovarian surface epithelium in vitro. Am J Obstet Gynecol 1995; 173:97-104.
8. Chadha S, Rao BR, Slotman BJ, van Vroonhoven CC, van der Kwast TH. An immunohistochemical evaluation of androgen and progesterone receptors in ovarian tumors. Hum Pathol 1993; 24:90-5.
9. Cardillo MR, Petrangeli E, Aliotta N, Salvatori L, Ravenna L, Chang C, Castagna G. Androgen receptors in ovarian tumors: correlation with oestrogen and progesterone receptors in an immunohistochemical and semiquantitative image analysis study. J Exp Clin Cancer Res 1998; 17:231-7.
10. Shaw PA, Rittenberg PV, Brown TJ. Activation of androgen receptor-associated protein 70 (ARA70) mRNA expression in ovarian cancer. Gynecol Oncol 2001; 80:132-8.
11. Li AJ, Lerner DL, Gapuzan MR, Karlan BY. AIB1 polymorphisms predict aggressive ovarian cancer phenotype. Cancer Epidemiol Biomarkers Prev 2005; 14:2919-22.
12. Berchuck A, Rodriguez G, Olt G, et al. Regulation of growth of normal ovarian epithelial cells and ovarian cancer cell lines by transforming growth factor-ß. Am J Obstet Gynecol 1992; 166:676-84.
13. Havrilesky LJ, Hurteau JA, Whitaker RS, et al. Regulation of apoptosis in normal and malignant ovarian epithelial cells by transforming growth factor ß. Cancer Res 1995; 55:944-8.
14. Hurteau JA, Rodriguez GC, Whitaker RS, et al. Transforming growth factor-ß inhibits proliferation of human ovarian cancer cells obtained from ascites. Cancer 1994; 74:93-9.
15. Pasche B, Kolachana P, Nafa K, et al. TßR-I (6A) is a candidate tumor susceptibility allele. Cancer Res 1999; 59:5678-82.
16. Wang J, Sun L, Myeroff L, et al. Demonstration that mutation of the type II transforming growth factor ß receptor inactivates its tumor suppressor activity in replication error-positive colon carcinoma cells. J Biol Chem 1995; 270:22044-9.
17. Abe T, Ouyang H, Migata T, et al. The somatic mutation frequency of the transforming growth factor ß receptor type II gene varies widely among different cancers with microsatellite instability. Eur J Surg Oncol 1996; 22:474-7.
18. Evangelou A, Jindal SK, Brown TJ, Letarte M. Downregulation of TGFß receptors by androgen in ovarian cancer cells. Cancer Res 2000; 60:929-35.
19. Evangelou A, Letarte M, Jurisica I, et al. Loss of coordinated androgen regulation in nonmalignant ovarian epithelial cells with BRCA1/2 mutations and ovarian cancer cells. Cancer Res 2003; 63:2416-24.
20. Yamada SD, Baldwin RL, Karlan BY. Ovarian carcinoma cell cultures are resistant to TGFbeta1-mediated growth inhibition despite expression of functional receptors. Gynecol Oncol 1999; 75:72-7.
21. Elliott RL, Blobe GC. Role of transforming growth factor beta in human cancer. J Clin Oncol 2005; 9: 2078-93.
22. Chipuk JE, Cornelius SC, Pultz NJ, et al. The androgen receptor represses transforming growth factor-b signaling through interaction with Smad3. J Biol Chem 2002; 277:1240-8.
23. Kang HY, Lin HK, Hu YC, Yeh S, Huang KE, Chang C. From transforming growth factor-beta signaling to androgen action: identification of Smad3 as an androgen receptor coregulator in prostate cancer cells. Proc Natl Acad Sci USA 2001; 98:3018-23.
24. Kang HY, Huang KE, Chang SY, Ma WL, Lin WJ, Chang C. Differential modulation of androgen receptor-mediated transactivation by Smad3 and tumor suppressor Smad4. J Biol Chem 2002; 277:43749-56.
25. Zhu ML, Partin JV, Bruckheimer EM, Strup SE, Kyprianou N. TGFß signaling and androgen receptors status determine apoptotic cross-talk in human prostate cancer cells. Prostate 2008; 68:287-95.
26. van der Poel HG. Androgen receptor and TGFbeta1/Smad signaling are mutually inhibitory in prostate cancer. Eur Urol 2005; 48:1051-8.
27. Cross M, Dexter TM. Growth factors in development, transformation and tumorigenesis. Cell 1991; 64:271-80.
28. Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. New Engl J Med 2008; 358:1160-74.
29. Lafky JM, Wilken JA, Baron AT, Maihle NJ. Clinical implications of the ErbB/epidermal growth factor (EGF) receptor family and its ligands in ovarian cancer. Biochimica et Biophysica Acta 2008; 1785:232-65.
30. Abdollahi A, Gruver BN, Patriotis C, Hamilton TC. Identification of epidermal growth factor-responsive genes in normal rat ovarian surface epithelial cells. Biochem Biophys Res Commun 2003; 307:188-97.
31. Doraiswamy V, Parrott JA, Skinner MK. Expression and action of transforming growth factor alpha in normal ovarian surface epithelium and ovarian cancer. Biol Reprod 2000; 63:789-96.
32. Choi JH, Choi KC, Auersperg N, Leung PC. Gonadotropins upregulate the epidermal growth factor receptor through activation of mitogen-activated protein kinases and phosphatidyl-inositol-3-kinase in human ovarian surface epithelial cells. Endocr Relat Cancer 2005; 12:407-21.
33. McClellan M, Kievit P, Auersperg N, Rodland K. Regulation of proliferation and apoptosis by epidermal growth factor and protein kinase C in human ovarian surface epithelial cells. Exp Cell Res 1999; 246:471-9.
34. Alper O, Bergmann-Leitner ES, Bennett TA, et al. Epidermal growth factor receptor signaling and the invasive phenotype of ovarian carcinoma cells. J Natl Cancer Inst 2001; 93:1375-84.
35. Lassus H, Sihto H, Leminen A, et al. Gene amplication, mutation and protein expression of EGFR and mutations of ErbB2 in serous ovarian carcinoma. J Mol Med 2006; 84:671-81.
36. Strawn LM, Shawver LK. Tyrosine kinases in disease: overview of kinase inhibitors as therapeutic agents and current drugs in clinical trials. Ex Opin Invest Drugs 1998; 7:553-73.
37. Ilekis JV, Connor JP, Prins GS, et al. Expression of epidermal growth factor and androgen receptors in ovarian cancer. Gynecol Oncol 1997; 66:250-4.
38. Bonaccorsi L, Carloni V, Muratori M, et al. Androgen receptor expression in prostate carcinoma cells suppresses alpha6heta4integrin-mediated invasive phenotype. Endocrinology 2000; 141:3172-82.
39. Bonaccorsi L, Muratori M, Carloni V, et al. The androgen receptor associates with the epidermal growth factor receptor in androgen-sensitive prostate cancer cells. Steroids 2004; 69:549-52.
40. Zhang W, Razani B, Altschuler Y, et al. Caveolin-1 inhibits epidermal growth factorstimulated lamellipod extension and cell migration in metastatic mammary adenocarcinoma cells (MTLn3). Transformation suppressor effects of adenovirus-mediated gene delivery of caveolin-1. J Biol Chem 2000; 275:20717-25.
41. Bonaccorsi L, Nosi D, Muratori M, Formigli L, Forti G, Baldi E. Altered endocytosis of epidermal growth factor receptor in androgen receptor positive prostate cancer cell lines. J Mol Endocrinol 2007; 38:51-66.
42. Helzlsouer KJ, Alberg AJ, Gordon GB, Longcope C, Bush TL, Hoffman SC, Comstock GW. Serum gonadotropins and steroid hormones and the development of ovarian cancer. JAMA 1995; 247:1926-30.
43. Schildkraut J, Schwingl PJ, Bastos E, Evanoff A, Hughes C. Epithelial ovarian cancer risk among women with polycystic ovarian syndrome. Obstet Gynecol 1996; 88:554-9.
44. Wynder EL, Dodo H, Barber HR. Epidemiology of cancer of the ovary. Cancer 1969; 23:352-70.
45. Mink PJ, Folsom AR, Sellers TA, Kushi LH. Physical activity, waist-to-hip ratio, and other risk factors for ovarian cancer: a follow-up study of older women. Epidemiology 1996; 7:38-45.
46. Rinaldi S, Dossus L, Lukanova A, et al. Endogenous androgens and risk of epithelial ovarian cancer: results from the European Prospective Investigation into Cancer and Nutrition. Cancer Epidemiol Biomarkers Prev 2007; 16:23-9.
47. Tworoger SS, Lee IM, Buring JE, Hankinson SE. Plasma androgen concentrations and risk of incident ovarian cancer. Am J Epidemiol 2008; 167:211-8.
48. Santarosa M, Bidoli E, Gallo A, Steffan A, Boiocchi M, Viel A. Polymorphic CAG repeat length within the androgen receptor gene: identification of a subgroup of patients with increased risk of ovarian cancer. Oncol Rep 2002; 9:639-44.
49. Terry KL, De Vivo I, Titus-Ernstoff L, Shih MC, Cramer DW. Androgen receptor cytosine, adenine, guanine repeats and haplotypes in relation to ovarian cancer risk. Cancer Res 2005; 65:5974-81.
50. Schildkraut JM, Murphy SK, Palmieri RT, et al. Trinucleotide repeat polymorphisms in the androgen receptor gene and risk of ovarian cancer. Cancer Epidemiol Biomarker Prev 2007; 16:473-80.
51. Powell IJ, Land SJ, Dey J, Heilbrun LK, Hughes MR, Sakr W, Everson RB. The impact of CAG repeats in exon 1 of the androgen receptor on disease progression after prostatectomy. Cancer 2005; 103:528-37.
52. Nam RK, Elhaji Y, Krahn MD, Hakimi J, Ho M, Chu W, Sweet J, Trachtenberg J, Jewett MA, Narod SA. Significance of the CAG repeat polymorphism of the androgen receptor gene in prostate cancer progression. J Urol 2000; 164:567-72.
53. Strom SS, Gu Y, Zhang H, Troncoso P, Babaian RJ, Pettaway CA, Shete S, Spitz MR, Logothetis CJ. Androgen receptor polymorphisms and risk of biochemical failure among prostatectomy patients. Prostate 2004; 60:343-51.
54. Li AJ, Baldwin RL, Karlan BY. Short androgen receptor allele length is a poor prognostic factor in epithelial ovarian carcinoma. Clin Cancer Res 2008; 9:3667-73.
55. Levine DA, Boyd J. The androgen receptor and genetic susceptibility to ovarian cancer: results from a case series. Cancer Res 2001; 61:908-11.
56. Yousef GM, Fracchioli S, Scorilas A, et al. Steroid hormone regulation and prognostic value of the human kallikrein gene 14 in ovarian cancer. Am J Clin Pathol 2003; 119:346-55.
57. Motamed-Khorasani A, Jurisica I, Letarte M, et al. Differentially androgen-modulated genes in ovarian epithelial cells from BRCA mutation carriers and control patients predict ovarian cancer survival and disease progression. Oncogene 2007; 26:198-214.
58. Tumolo S, Rao BR, van der Burg ME, Guastalla JP, Renard J, Vermorken JB. Phase II trial of flutamide in advanced ovarian cancer: an EORTC Gynaecological Cancer Cooperative Group study. Eur J Cancer 1994; 30:911-4.
59. Levine D, Park K, Juretzka M, et al. A phase II evaluation of goserelin and bicalutamide in patients with ovarian cancer in second or higher complete clinical disease remission. Cancer 2007; 110:2448-56.